Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril

K. Repova, P. Stanko, T. Baka, K. Krajcirovicova, S. Aziriova, J. Hrenak, A. Barta, S. Zorad, RJ. Reiter, M. Adamcova, F. Simko

. 2022 ; 13 (-) : 978337. [pub] 20220913

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22031719

Lactacystin is a specific proteasome inhibitor that blocks the hydrolysis of intracellular proteins by ubiquitin/proteasome system inhibition. The administration of lactacystin to rats induced hypertension and remodeling of the left ventricle and aorta. This study tested whether lactacystin induces structural and fibrotic rebuilding of the kidneys and whether melatonin and captopril can prevent these potential changes. Six weeks of lactacystin administration to rats increased their average systolic blood pressure (SBP). In the kidneys, lactacystin reduced glomerular density, increased the glomerular tuft area, and enhanced hydroxyproline concentrations. It also elevated the intraglomerular proportion including the amounts of collagen (Col) I and Col III. Lactacystin also raised the tubulointerstitial amounts of Col I and the sum of Col I and Col III with no effect on vascular/perivascular collagen. Six weeks of captopril treatment reduced SBP, while melatonin had no effect. Both melatonin and captopril increased glomerular density, reduced the glomerular tuft area, and lowered the hydroxyproline concentration in the kidneys. Both drugs reduced the proportion and total amounts of intraglomerular and tubulointerstitial Col I and Col III. We conclude that chronic lactacystin treatment stimulated structural and fibrotic remodeling of the kidneys, and melatonin and captopril partly prevented these alterations. Considering the effect of lactacystin on both the heart and kidneys, chronic treatment with this drug may be a prospective model of cardiorenal damage suitable for testing pharmacological drugs as protective agents.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031719
003      
CZ-PrNML
005      
20231121101905.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2022.978337 $2 doi
035    __
$a (PubMed)36176443
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
245    10
$a Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril / $c K. Repova, P. Stanko, T. Baka, K. Krajcirovicova, S. Aziriova, J. Hrenak, A. Barta, S. Zorad, RJ. Reiter, M. Adamcova, F. Simko
520    9_
$a Lactacystin is a specific proteasome inhibitor that blocks the hydrolysis of intracellular proteins by ubiquitin/proteasome system inhibition. The administration of lactacystin to rats induced hypertension and remodeling of the left ventricle and aorta. This study tested whether lactacystin induces structural and fibrotic rebuilding of the kidneys and whether melatonin and captopril can prevent these potential changes. Six weeks of lactacystin administration to rats increased their average systolic blood pressure (SBP). In the kidneys, lactacystin reduced glomerular density, increased the glomerular tuft area, and enhanced hydroxyproline concentrations. It also elevated the intraglomerular proportion including the amounts of collagen (Col) I and Col III. Lactacystin also raised the tubulointerstitial amounts of Col I and the sum of Col I and Col III with no effect on vascular/perivascular collagen. Six weeks of captopril treatment reduced SBP, while melatonin had no effect. Both melatonin and captopril increased glomerular density, reduced the glomerular tuft area, and lowered the hydroxyproline concentration in the kidneys. Both drugs reduced the proportion and total amounts of intraglomerular and tubulointerstitial Col I and Col III. We conclude that chronic lactacystin treatment stimulated structural and fibrotic remodeling of the kidneys, and melatonin and captopril partly prevented these alterations. Considering the effect of lactacystin on both the heart and kidneys, chronic treatment with this drug may be a prospective model of cardiorenal damage suitable for testing pharmacological drugs as protective agents.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stanko, Peter $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Baka, Tomas $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Hrenak, Jaroslav $u Medbase, Bern, Switzerland
700    1_
$a Barta, Andrej $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia
700    1_
$a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $7 xx0310348
700    1_
$a Reiter, Russel J $u Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, United States
700    1_
$a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $u 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 13, č. - (2022), s. 978337
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36176443 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20231121101902 $b ABA008
999    __
$a ok $b bmc $g 1889617 $s 1183052
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 13 $c - $d 978337 $e 20220913 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20230119

Find record

Citation metrics

Archiving options